Skip to main content
Premium Trial:

Request an Annual Quote

Natera to Raise $250M in Follow-on Stock Offering

NEW YORK – Natera said on Wednesday that it has launched a follow-on public offering of $250 million of shares of its common stock.

In a shelf registration statement filed with the US Securities and Exchange Commission, Natera said that at an assumed public offering price of $61.79 per share, the last reported sale price of its common stock on Sept. 8, it would be offering 4,045,962 shares of its common stock.

Natera also expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million worth of shares of its common stock at the public offering price, less the underwriting discounts and commissions.

JP Morgan, Morgan Stanley, Cowen, and SVB Leerink are acting as joint book-running managers for the offering, while Baird and Craig-Hallum Capital Group are acting as co-managers.

In April, Natera had offered $250 million worth of convertible senior notes.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more